This project has been flagged by a community member as inappropriate due to reason below.*
Slingshot & STAT have partnered to provide you with interviews with experts led by STAT's reporters. This call is on:

Discussing Biogen's Regulatory Chances for Aducanumab in Alzheimer's with a Regulatory Expert.

Ticker(s): BIIB

Who's the expert?

A regulatory expert or Alzheimer's KOL who has familiarity with the FDA and the Alzheimer's regulatory division.

Interview Goal
While we wouldn’t normally take note of a new drug submission to the Food and Drug Administration, any development regarding Biogen’s (BIIB) controversial Alzheimer’s drug aducanumab is significant enough to matter. Biogen has told investors that it will complete the aducanumab filing to the FDA in “early 2020” — which sounds like the first quarter. Join us for a call with a regulatory expert as we opine on the review.

Are You Interested In These Questions?



10Days Left to Join Project

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.